LesinskiLab
@lesinskilab.bsky.social
The Lesinski Laboratory is focused on understanding the interactions between the immune system and cancer. opinions are my own. #immunotherapy #GICancer
#sitc election…only one more day to vote!!! Would be very grateful for the opportunity to serve this great organization as an at large director.
Society for Immunotherapy of Cancer@sitcancer.bsky.social · 4mo agoLearn about 2026 SITC At-Large Director candidate, Gregory B. Lesinski, PhD, MPH (Winship Cancer Institute of Emory University). Read about Dr. Lesinski: https://www.sitcancer.org/get-involved/2026-sitc-election#lesinski
#sitc election voting is now open!!! Don’t delay shaping the future of #immunotherapy with your vote. Feel free to throw a vote my way for “at large director”, but there is no losing as ALL Candidates are amazing!
Society for Immunotherapy of Cancer@sitcancer.bsky.social · 5mo agoThe 2026 SITC Election is now open! SITC members are electing the society’s next Vice President, Secretary/Treasurer and three At-Large Directors. The election closes on Friday, May 15 at 11:59 p.m. EDT. https://www.sitcancer.org/get-involved/2026-sitc-election
am humbled to be on the #sitc ballot as an at large candidate to support this #immunotherapy driven organization! Would love your vote on May 1st to help @sitcancer.bsky.social
Society for Immunotherapy of Cancer@sitcancer.bsky.social · 5mo agoThe #SITC election opens May 1. The VP candidate who receives the most votes will begin their 2-year term in 2027 before ascending to the role of SITC President in 2028. Read the biographies + platform statements of this year’s candidates: https://www.sitcancer.org/get-involved/2026-sitc-election#vp
🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back. 🔗 Read: www.cell.com/cancer-cell/... 🧬This unexpected immune duo sparks tumor immunity. 🖼️Image: See schematic Th17/B cell antitumor action!
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity
Cole et al. report that adoptively transferred, tumor-specific Th17 cells engage host B cells and drive B cell proliferation and differentiation. These Th17 cells require B cells for sustained immunit...
cell.com
Check out our new paper in Hepatology on how myeloid cells limit immunotherapy in preclinical cholangiocarcinoma models! Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others! pubmed.ncbi.nlm.nih.gov/40590857/
Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma - PubMed
These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant pre-...
pubmed.ncbi.nlm.nih.gov
Cool pre-print alert! insight into how neoAg alter trafficking of adoptively transferred T cells! Proud to be part of this stellar collaboration with @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu www.biorxiv.org/content/10.1...
Neoantigens drive adoptively transferred CD8 T cells to long-lived effectors mediated by lymph node trafficking
Adoptive transfer of neoantigen-reactive T lymphocytes mediates potent responses against solid tumors in patients while often limiting toxicity to normal tissues; however, the mechanisms governing the...
biorxiv.org
On April 23, participate in 5 topic-driven sessions at SITC’s ACI: A Focus on Gastrointestinal Cancers program! Gain in-depth education on all aspects of clinical implementation of IO for GI cancers. Advance your clinical practice and earn free CME: ow.ly/SPaR50VEJbg @lesinskilab.bsky.social 🧪
www.biorxiv.org/content/10.1... Excited to share our preprint on comparing Human Primary and metastatic #pancreaticcancer!!!
High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Signatures Between Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Our understanding of the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) primarily stems from murine models or primary patient tumors. While metastatic tumors have generally less ...
biorxiv.org
Grateful to #kevinvanderjeught for the opportunity to visit the powerhouse #GIoncology program at #umiami Sylvester cancer center @drjashdatta.bsky.social #nipunmerchant
So very proud of our newly minted Dr. Maggie Phillips! @winshipatemory.bsky.social She showcased her amazing translational oncology experience in today’s public defense!
Inspiring (as always) @cholangiocarcinoma.bsky.social annual meeting comes to a close. Our @winshipatemory.bsky.social team returns motivated by survivors, patients and caregivers to make a difference! @megen-w.bsky.social @chrystalpaulos.bsky.social
Tremendous talk by Dr. Kailey Oppat @winshipatemory.bsky.social on #FGFR and #IDH interaction with #immune signatures in #cholangiocarcinoma via collab w #carisls @cholangiocarcinoma.bsky.social annual meeting!
Proud to report our new manuscript describing clinical Trial results of dual Hsp90/PD1 inhibition in #colorectalcancer. @winship Full article: XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial www.tandfonline.com/doi/full/10....
XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial
We conducted a phase Ib/II clinical trial to evaluate the safety, feasibility, and clinical activity of combining pembrolizumab (anti-PD-1) with XL888 (Hsp90 inhibitor) in patients with advanced co...
tandfonline.com
Very well done article on pancreatic cancer @wsj.com highlighting hope in a devastating disease. Adding the note that fundamental discoveries related to Kras were derived from NIH funding supported by tax dollars well spent.
The Wall Street Journal@wsj.com · 2y agoPancreatic cancer remains one of the toughest cancers to treat. But newer therapies entering clinical trials are giving doctors hope. on.wsj.com/3Dp4Gfs
@immunegirl.bsky.social teaching us all a thing or two about TCRs! @sitcancer.bsky.social winter school master class!
Stellar talk by @zach-buchwald.bsky.social @winshipatemory.bsky.social at SITC winter school!
Chrystal Paulos@chrystalpaulos.bsky.social · 2y agoExcellent talk by Dr. Zach Buchwald @zach-buchwald.bsky.social from @winshipatemory.bsky.social on immunotherapy in special patient populations. Talks about his amazing work on brain meta and circadian rhythm in immunity!! #CIWS2025 @sitcancer.bsky.social
@chrystalpaulos.bsky.social @winshipatemory.bsky.social knocks it out of the park @sitcancer.bsky.social winter school on the power of CD4 T cells!
Dr. Yina Huang brings the house down with her AMAZING talk on harnessing synthetic biology to augment next generation cell therapy for cancer patients at Winter School @sitcancer.bsky.social 💥
We’re thrilled to welcome Dr. Perrine Verdys and Shawez Khan from Denmark and Moldir Konysbekova from Kazakhstan to our 2025 Cancer Immunotherapy Winter School program. Thanks to all the attendees that made the trip to Austin! #CIWS2025
Congrats to my brilliant collaborator and friend @chrystalpaulos.bsky.social in this important leadership role!
Winship Cancer Institute of Emory University@winshipcancer.emory.edu · 2y ago🎉Congrats to Emory cancer immunologist Chrystal Paulos, PhD, (@chrystalpaulos.bsky.social) who has been named co-leader of the Cancer Immunology Research Program at Winship. ➡️ brnw.ch/21wQB3h
BREAKING NEWS: CDC orders mass retraction and revision of submitted research across all science and medicine journals. Banned terms must be scrubbed. Goes beyond MMWR +other CDC pubs. Applies to research already submitted to top medical journals. Take a look. open.substack.com/pub/insideme...
BREAKING NEWS: CDC orders mass retraction and revision of submitted research across all science and medicine journals. Banned terms must be scrubbed.
Any unpublished manuscript mentioning certain topics, including gender and "LGBT," must be pulled or revised.
open.substack.com
Time is running out! Prospective post docs please apply to our event to learn about @winshipatemory.bsky.social Apply at this link brnw.ch/21wPrWk
Important lab bench to clinical trial study led by Bassel El-Rayes, MD and many other colleagues on a new combination chemo regimen in pancreatic cancer. Honored to collaborate in this effort! www.cell.com/cell-reports...
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine
Nagaraju et al. have identified that paricalcitol (P) plus hydroxychloroquine (H) potentiates the efficacy of gemcitabine (G) in PDAC. GPH treatment induces ER stress and autophagy with M1 polarization and T cell activation. These findings in PDAC patient-derived data highlight the potential translational impact of GPH therapy in improving clinical outcomes.
cell.com
Join us on March 13-14, 2025, for postdoctoral recruitment event at Winship! Network with mentors and postdocs, and explore Emory's research and career resources. 📅 Apply by January 10, 2025 🔗 Details & Application: brnw.ch/21wPrWk #PostdocOpportunities #CancerResearch #WinshipResearch
Winship Postdoctoral Fellow Recruitment Event
brnw.ch
We are accepting poster abstract submissions for our upcoming annual conference. This is an opportunity to present late-breaking results, ongoing research projects, and innovative work in cholangiocarcinoma research. Submit an abstract here: cholangiocarcinoma.org/annual-confe...
Outstanding clinical presentation for neoadjuvant cutaneous squamous cell carcinoma by @winshipatemory.bsky.social Dr Michael Lowe #bridge24
And the last debate! Dr Emens vs Dr Khlief ADC vs Bispecifics!
